Cantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized ...
Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against ...
BofA downgraded PepGen (PEPG) to Underperform from Neutral with a price target of $3, down from $6, after the FDA placed a clinical hold on the ...
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on PolyPid (PYPD – Research Report). The associated price target ...
GlobalData on MSN15h
Most significant clincal trials of 2024From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read ...
Diogo Costa often sees data like a silhouette, an outline of a construct far bigger than its parts.
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first ...
The report concludes with future market projections of each segmentation and analyst recommendations ... The research includes segmentation of the THAILAND CLINICAL LABORATORY market based on types, ...
For the fourth quarter of 2024, Mr. Hacking lowered his earnings per share estimate by a penny to 93 US cents, while his full ...
9 déc 2024 Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders Sirius Therapeutics today ...
Perspective Therapeutics is a biotech company with promising oncology applications in radiopharmaceuticals. Find out why I ...
GenAI is generative, focusing on creating new content based on learned data, whether it’s text, images or molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback